Receptor News and Research

RSS

Potential mosquito-based malaria vaccine could be a step closer

A promising type of vaccine designed to eradicate malaria by blocking parasite transmission could be a step closer, as a result of experts uncovering new information about the targeted protein.

17 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.

16 Jun 2015

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.

15 Jun 2015

LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

Clinicians at Ludwig-Maximilians-Universitaet in Munich have elucidated a mechanism involved in determining the lifespan of antibody-producing cells, and identified a promising new biomarker for monitoring autoimmune diseases like multiple sclerosis and lupus erythematosus.

15 Jun 2015

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).

12 Jun 2015

Researchers identify two critical mutations that allow MERS virus to transmit from bats to humans

Researchers have identified two critical mutations allowing the deadly Middle East Respiratory Syndrome (MERS) virus to transmit from bats to humans. The findings were published in the most recent edition of the Journal of Virology.

11 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Two fragile X proteins play crucial role in proper development of neurons

Fragile X syndrome is the most common inherited intellectual disability and the greatest single genetic contributor to autism. Unlocking the mechanisms behind fragile X could make important revelations about the brain.

11 Jun 2015

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.

10 Jun 2015

New study shows that estrogen receptors vanish in cervical cancer tumors

Scientists have prior evidence that the hormone estrogen is a major driver in the growth of cervical cancer, but a new study examining genetic profiles of 128 clinical cases reached a surprising conclusion: Estrogen receptors all but vanish in cervical cancer tumors.

10 Jun 2015

UC Davis research paves way for designing more effective drugs to relieve pain

UC Davis researchers have identified the molecular interactions that allow capsaicin to activate the body's primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain. Their study appeared online June 8 in the journal Nature Chemical Biology.

10 Jun 2015

Researchers identify potential treatment option for childhood leukemia

Researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center are reporting a potentially important discovery in the battle against one of the most devastating forms of leukemia that accounts for as many as one in five children with a particularly aggressive form of the disease relapsing within a decade.

10 Jun 2015

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

9 Jun 2015

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

EUROSARC, European Clinical trials in Rare Sarcomas within an integrated translational trial network, has launched a phase II trial of Linsitinib for patients with relapsed and/or refractory Ewing Sarcoma. The trial, EORTC 1225 / OCTO 038, aims to establish pharmacodynamic responses in Ewing sarcoma tumors to Linsitinib using functional imaging and biopsies, and toxicity and clinical outcomes.

9 Jun 2015

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Quality control is important - this is not only applicable to industrial production but also true for all life processes. However, whereas an enterprise can start a large-scale recall in case of any doubt, defects in the quality control systems of cells are often fatal.

9 Jun 2015

Findings could lead to new therapies that stop breast cancer progression

Scientists have discovered a trigger that allows breast cancer cells to spread to the lungs. They have found that blocking the signals in mice with breast cancer greatly reduces the number of secondary tumours found in the lungs.

9 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Receptor News and Research

Potential mosquito-based malaria vaccine could be a step closer

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

LMU clinicians reveal mechanism involved in determining lifetime of antibody-producing cells

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

Researchers identify two critical mutations that allow MERS virus to transmit from bats to humans

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Two fragile X proteins play crucial role in proper development of neurons

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

New study shows that estrogen receptors vanish in cervical cancer tumors

UC Davis research paves way for designing more effective drugs to relieve pain

Researchers identify potential treatment option for childhood leukemia

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Study shows how GLP-1 receptor agonists modify the brain's response to food

Phase II clinical trial of Linsitinib launched in patients with advanced Ewing sarcoma

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Findings could lead to new therapies that stop breast cancer progression

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News